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Abstract
The complexity of the process of metastasis is widely recognized. We report herein on a recurrent feature of high
compared to lowmetastatic cells that is linked to their ability to survive early after their arrival at secondary sites. Using
novel fluorescent-based imaging strategies that assess tumor cell interaction with the lung microenvironment, we
have determined that most high and low metastatic cells can be distinguished within 6 hours of their arrival in the
lung and further that this difference is defined by the ability of highmetastatic cells to resist apoptosis at the secondary
site. Despite the complexity of the metastatic cascade, the performance of cells during this critical window is highly
defining of their metastatic proclivity. To explore mechanisms, we next evaluated biochemical pathways that may be
linked to this survival phenotype in highly metastatic cells. Interestingly, we found no association between the Akt
survival pathway and this metastatic phenotype. Of all pathways examined, only protein kinase C (PKC) activation
was significantly linked to survival of highly metastatic cells. These data provide a conceptual understanding of a
defining difference between high and low metastatic cells. The connection to PKC activation may provide a biologic
rationale for the use of PKC inhibition in the prevention of metastatic progression.
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Introduction
For many solid tumors, a common site of metastatic progression is the
lung. Metastasis includes a complex set of steps that involves inter-
action between the tumor and the tumor microenvironment [1,2].
An area of considerable interest has been the identification of genes
or proteins that contribute to or inhibit metastatic progression. High-
throughput genomic and proteomic approaches have fueled the in-
vestigative pipeline with many candidate genes and proteins that may
promote or inhibit metastasis [3–7]. It has been difficult to distinguish
those candidates that are markers of metastatic progression from those
that are causally linked to metastasis. One approach to understand these
numerous candidates in a systemwide manner has been to identify
pathways that may connect various candidates. This approach has
the appeal of identifying points of convergence among various candi-
dates that may be critical to a complex biologic process like metastasis.
An alternative, non–mutually exclusive, and functionally driven ap-
proach has been to identify critical cellular processes or steps that most
define the metastatic phenotype of cancers. In such an approach, it is
understood that all biologic steps that are linked to metastatic progres-
sion are necessary; however, some of these steps may be readily achieved
by both high and low metastatic cells. The corollary suggests that some
steps are more defining of the metastatic phenotype and, as such, may
be most valuable to target therapeutically. If a functional hierarchy of
the steps of the metastatic cascade were available, an opportunity would
exist to focus on those genes/proteins that are functionally related to
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higher-priority steps in metastasis. Such an approach would provide
a basis to study of genes/proteins most critical to metastasis biology
and therapy.
Progress toward such a goal of dissecting the steps in the metastatic
cascade has been made possible using novel single-cell imaging strate-
gies. Indeed, Chambers et al. [8] have evaluated discrete steps in the
metastatic cascade using intravital imaging of metastatic cancer cells
as they arrived in the liver. More recent studies in brain and in other
tissues have allowed a similar understanding of critical steps in the
metastatic cascade [9–11]. Such an understanding of the pulmonary
metastatic phenotype is still lacking [12]. To help understand the biol-
ogy of metastasis to the lung, we previously described a fluorescent
imaging approach, single-cell videomicroscopy (SCVM) [13]. We first
used SCVM to ask how the cytoskeleton linker protein, ezrin, contrib-
uted to metastasis of pediatric osteosarcoma and rhabdomyosarcoma.
These studies indicated that ezrin played a critical role in metastasis
within hours of the arrival of metastatic cells in the lung [13]. Since
then, our experience with SCVM has expanded beyond the study of
ezrin alone. In a series of unrelated publications, focused on sarcoma
and breast cancer metastasis, we discovered that our findings with ezrin
were not unique. Indeed, despite a diversity of species (i.e., mouse and
human cells) and a variety of candidate proteins (both metastasis
suppressors and metastasis associated), nearly all high compared to
low metastatic cells could be distinguished within 6 hours of their entry
to the lung. Collectively, these data suggested that the events occurring
early after metastatic cells arrived in the lung are especially difficult for
cancer cells to overcome and seemed to repeatedly distinguish high
from low metastatic cells. It is reasonable that the study of these events
may provide a context to prioritize future consideration of putative
metastasis-associated genes related to both biology and therapy.
Using pairs of human and murine high and low metastatic breast
cancer and sarcoma cells, two cancer types with a proclivity for metas-
tasis to the lung, we now report on the specific cellular process that are
most defining of metastasis and present data on the biochemical path-
ways linked to this phenotype. Using SCVM and a more recently re-
ported ex vivo pulmonary metastasis assay (PuMA [14]) in which the
metastatic progression of GFP-expressing cancer cells, from a single cell
to the formation of multicellular colonies, in the mouse lung micro-
environment can be assessed in real time for up to 30 days, we deter-
mined that a distinguishing feature was the ability of highly metastatic
cells to avoid apoptosis within hours of their arrival in the lung. It is
interesting to note that this resistance against apoptosis, disproportion-
ately seen in highly metastatic cells, was not evident outside the context
of metastasis because the high and low metastatic pairs were not distin-
guishable by growth or proliferation in vitro. The connection between
apoptosis resistance and the cancer phenotype has been previously
recognized [12,15–17]. Our data now provide a metastasis-specific
context in which to consider the importance of apoptosis resistance
as part of the metastatic phenotype. This priority on resistance to
apoptosis early after arrival of cells in the lung now supports exam-
ination of molecular pathways causally linked to the drivers of the
metastasis biology. We were surprised to find no association be-
tween the classic Akt survival pathway and this metastatic pheno-
type. Indeed, of all the pathways examined, only protein kinase C
(PKC) activation was significantly linked to survival of highly meta-
static breast cancer and sarcoma cells within hours of their arrival in
the lung. The unique dependence on PKC activation was confirmed
in preclinical in vivo studies of pulmonary metastasis using inhibitors
of classic PKC isoforms.
Materials and Methods
Cell Lines and Media
The characterization and behavior of all the clonally related high
and low metastatic cell lines has been previously reported as indicated
below: murine osteosarcoma cells (high metastatic [met], K7M2; low
met, K7M2 AS ezrin 1.46 [AS1.46] and 1.52 [AS1.52]) [13,18]; the
human osteosarcoma cell lines (high met, HOS-MNNG [MNNG];
low met, HOS) [19]; the human soft tissue sarcoma cell lines (high
met, HT1080 sh-control; low met, HT1080 sh-gp78), provided by
Dr Allan M. Weissman (National Cancer Institute, Frederick, MD)
[20]; human mammary cancer cell lines (high met, H1-177 EDG2;
low met, H1-177), provided by Dr Patricia S. Steeg (National
Cancer Institute, Frederick, MD) [21]; the murine osteosarcoma
cell lines (high met, K7M3/FDN; low met, K7M3/neo), provided
by Dr Eugenie S. Kleinerman (The University of Texas MD Anderson
Cancer Center, Houston, TX) [22]; and the murine breast cancer cell
lines (high met, 4T1; low met, 67NR), provided by Dr Lalage M.
Wakefield (National Cancer Institute, Bethesda, MD) [23]. The
human breast cancer cells were also provided by Dr Wakefield
MDA-MB-231 All cell lines were maintained in vitro using Dulbecco
modified Eagle medium (Invitrogen, Carlsbad, CA) culture medium
containing 10% fetal bovine serum, L-glutamine (2 mmol), penicillin
(100 U/ml), and streptomycin (100 mg/L; Invitrogen) at 37°C in a
humidified 5% CO2 incubator.
Cell lines that expressed empty vector (EV AS1.46 and EV
AS1.52) and activated Akt AS1.46 (actAkt AS1.46) were maintained
in 6.7 μg/ml of puromycin (Sigma, St Louis, MO). Activated Akt
AS1.52 (actAkt AS1.52) was maintained in 10 μg/ml of puromycin
(Sigma). PT67 packaging cells (ATCC) were used for retroviral trans-
fection according to the manufacturer’s instruction. For all in vitro and
in vivo assays, cells were harvested using Trypsin/Versene (Invitrogen)
from 70% confluent cultures. Cell viability was assessed using trypan
blue and all cell lines used were from less than 20 passages. All cells were
verified mycoplasma free.
Retroviral Activated Akt Gene Infection
The murine stem cell virus (pMSCVpuro) (BD Biosciences, Palo
Alto, CA) was used for the construction of the retrovirus-encoding
activated Akt gene. Activated Akt DNA was amplified by standard
polymerase chain reaction technique using activated Akt1 in pUSEamp
complementary DNA (Upstate, Lake Placid, NY) as the template. The
synthesized DNA was digested with XhoI and BglII enzymes, purified,
and cloned to the pMSCVpuro vector. Packaging cells, PT67, were
transfected with Lipofectamine 2000 (Invtrogen) transfection reagent
following the manufacturer’s protocol. Transfected cell lines were
established by selection with 2.5 μg/ml of puromycin for 2 weeks,
and single-cell clones were selected for determination of the virus
titer. The virus titers were evaluated by culture with NIH3T3 cells.
For infection, AS1.46 and AS1.52 cells were cultured with retrovirus
containing PT67 cell culture supernatant in the presence of polybrane
(4 mg/ml; Sigma).
In Vivo/Ex Vivo SCVM Imaging [13]
Cell lines were transduced with pSICO-eGFP or p960-X1-685-
eGFP or fluorescently labeled using 5 μM 5-chloromethylfluorescein
diacetate (CMFDA; Invitrogen) according to the manufacturer’s rec-
ommendation. At 1 and 6 hours, after tail vein injection of 2.0 ×
105 cells, mice were euthanized by CO2 inhalation. Lungs were inflated
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using slow intratracheal injection of PBS and then imaged by inverted
fluorescent videomicroscopy (Leica DM IRB, Buffalo Grove, IL) at a
magnification of ×100. Ten random frames were captured and analyzed
using OpenLab software (Improvision, Waltham, MA) to define and
count fluorescent (green) CMFDA tumor events larger than 10 pixels.
The total numbers of events per lung per mouse were summarized as a
mean of five mice per time point [13]. Animal care and use were in
accordance with the guidelines of the National Institutes of Health’s
Animal Care and Use Committee.
Ex Vivo Terminal Transferase dUTP Nick End Labeling
and In Vivo Apoptosis Detection Assay
Using 15-μm paraffin sections made from whole lung 1, 3, and
6 hours after CMFDA- or GFP-labeled tumor cell injection, terminal
transferase dUTP nick end labeling (TUNEL) assay was performed us-
ing the in situ Cell Death Detection Kit, TMR red (Roche, Penzberg,
Germany). Antigen retrieval solution (Dako, Carpinteria, CA) was pre-
heated by microwave oven, and slides were incubated with the heating
solution 10 minutes. The whole lung was examined using fluorescence
microscopy to enumerate double-positive green/red apoptotic tumor
cells and Zeiss LMS 510 NLO confocal microscopy system (Zeiss,
Thornwood, NY). Apoptotic tumor cells were also imaged using fluo-
rescent detection of activated caspase 3 (FLIVO; Immunohistochemis-
try Technologies, LLC, Bloomington, MN). One hour after tumor
cell injection, whole lung fluorescence microscopy quantified double-
positive green/red tumor cells experiencing caspase cleavage.
Western Blot Analysis and Kinase Assay
Cells were lysed in either SDS or RIPA buffer (150 mM NaCl,
50mMTris, pH 8.0, 0.1% SDS, 0.5% deoxycholate, 1%NP-40) with
proteinase inhibitor cocktail (Roche). Protein lysates (20-40 μg/lane),
as determined by Bio-Rad protein assay, were separated in 4% to 20%
or 6% SDS-PAGE followed by electrophoretic transfer to a nitrocellu-
lose membrane (Invitrogen). The membranes were blocked with 5%
nonfat dried milk in TBS–Tween 20 (20 mM Tris-HCl, pH 7.5,
8 g/L sodium chloride, 0.1% Tween 20) and incubated with primary
antibody: 1:1000, anti–phospho-Akt (Ser473), anti-Akt, anti–p70 S6
kinase, anti–phospho-p70 S6 kinase, anti–ezrin/radixin/moesin
(ERM), anti–phospho-ERM, anti-FAK, anti–phospho-FAK, anti-
p44/42, anti–phospho-p44/42 (Cell Signaling, Beverly, MA); or
1:10,000, anti–β-actin (Sigma) overnight at 4°C. SuperSignal West
Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL)
was used for detection of antibody. For Akt kinase, activity was assessed
using phosphorylation of Akt substrate, glycogen synthase kinase-3,
according to the manufacturer’s instructions (Cell Signaling).
In Vivo/Ex Vivo PuMA [14]
GFP-positive tumor cells (K7M2, AS1.46, AS1.52, 4T1, and
MDA-MB-231) (2 × 105) were delivered by tail vein injection to
either female Balb/c (Taconic, Hudson, NY) or SCID/Beige (Charles
Rivers, Wilmington, MA). Within 15 minutes of tumor cell injection,
mice were euthanized with CO2 inhalation, and lungs were injected
with a mixed agarose/medium solution. Lung sections for PuMA,
generated as described [14], were incubated at 37°C in humidified
conditions of 5% CO2. Pathway inhibitor doses that did not inhibit
cell proliferation in vitro but did modulate intended targets were
selected: 1 μMAkt inhibitor VIII (EMD Chemicals, Inc, Gibbstown,
NJ), a PH domain-dependent inhibitor of Akt1/Akt2, 5 μM PI3
kinase activator (740 Y-P; Tocris Bioscience, Ellisville, MO), 25 nM
mTOR inhibitor (Torin1; kind gift from Dr Nathanael S. Gray,
Dana-Farber Cancer Institute and David M. Sabatini, Whitehead
Institute/MIT/HHMI), PKC inhibitor (50 nMUCN-01 [EMDChem-
icals, Inc] or 5 μM Ro31-8220 [Axxora Life Science, Inc, San Diego,
CA]), 1 μM Src inhibitor (AZD0530/saracatinib; AstraZeneca Phar-
maceuticals LP, Wilmington, DE), 10 μM MAPK inhibitor (EMD
Chemicals, Inc), or DMSO was added to medium and changed every
other day. PuMA images were captured and analyzed as previously de-
scribed [14]. The inhibitor or activator index was calculated by dividing
the tumor burden (area of fluorescence), in the inhibitor- or activator-
treated lung section, by that of the control-treated lung section.
In Vivo Orthotopic Primary Tumor Growth and Experimental
Metastasis Assays
Two million K7M2 murine osteosarcoma cells were injected into
an orthotopic paraosseous location, adjacent to the left proximal
tibia, in 4-week-old female Balb/c mice (Charles River, Wilmington,
MA). After primary tumors reached 1 cm size, mice were treated with
UCN-01 (7 mg/kg per day) or vehicle intraperitoneally, 5 days on and
2 days off. Longest tumor dimension was monitored by caliper every
other day until humane end point of 1.5 cm tumor was achieved.
Experimental metastases were achieved by tail vein injection of 1.0 ×
106 cells. Eighteen days after cell injection, UCN-01 (7 or 14 mg/kg
per day) or vehicle was administered for 4 days. Mice were euthanized,
and lungs were extracted and fixed in formalin. The lung was stained
hematoxylin and eosin and imaged with ImageScope (Aperio Technol-
ogies, Inc, Vista, CA). Pulmonary metastatic tumor area was quantified
by measuring the tumor area in the whole lung.
Statistical Analysis
Differences in SCVM was analyzed by a nonparametric two-tailed
t test. TUNEL and in vivo apoptosis detection were analyzed with a
Fisher exact test. PuMA was analyzed by a one-way analysis of variance
(ANOVA). Statistical analyses were performed using GraphPad Prism
version 4.0C or InStat version 3.1a for Macintosh (GraphPad Software,
La Jolla, CA). Statistical significance was defined as P ≤ .05.
Results
Defining the Phenotype of Highly Metastatic Cancer Cells
We previously reported the use of SCVM as a means to evaluate
the influence of specific genes/proteins on the metastatic progression
of both breast cancer and sarcoma cells to the lung (Figure 1). As
expected, using this assay, we found that all cancer cell lines that
we evaluated underwent significant attrition after their arrival in the
lung (so called metastatic inefficiency); however, we were struck by
the fact that, in five of the six studies of high and low isogenic meta-
static cell lines, the high metastatic cells could be distinguished from
the low metastatic cells within 6 hours of their arrival in the lung (Fig-
ures 1 and W1). We speculated that the cause of this early impact on
metastatic efficiency may be the result of death of single metastatic
cells in the lung or the dislodgement/migration of previously arrested
metastatic cells back into the circulation. These data suggested that
despite the complexity of the metastatic cascade, the events occurring
early after the arrival of metastatic cells in the lung were unique and
represented a stringent test for high versus low metastatic cells. The
studies included two cancer types (breast cancer and sarcoma) recog-
nized for progression to the lung. Exemplary of the behavior of the
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high and low metastatic cells, the K7M2 and AS1.46 pair is defined
by differences in the expression of ezrin, a cytoskeleton linker protein
associated with metastasis [13]. When using SCVM, the highly meta-
static K7M2 cells yielded a predictable pattern of metastatic ineffi-
ciency with 15% of cells being retained in the lung within 6 hours
compared with the less metastatic AS1.46 (Figure 1A) and AS1.52
cells (Figure W1A) where less than 4% retention occurred. Similar
trends were seen in studies that included the inhibition of metastasis
by the E3 ubiquitin ligase, gp78, and its association with the trans-
membrane metastasis suppressor KAI1 (also known as CD82), in soft
tissue sarcoma [20], the transcriptional regulation lysophosphatidic
acid receptor by the metastasis suppressor Nm23-H1 in breast cancer
cells [21], the role of Gemin5 as a regulator of the Nm23 phenotype
in breast cancer cells [24], and the suppressive influence of the Fas
signaling pathway in osteosarcoma [22]. The only biologic outlier
in these studies of high and low metastatic cell line pairs was the com-
parison of the highly metastatic MNNG and less metastatic HOS
osteosarcoma cells, which differ in the expression of an activated form
of MET [25]. Both high (MNNG) and low (HOS) metastatic cells
experienced similar levels of metastatic inefficiency (30% retention in
the lung; Figure W1B), suggesting that events that occur later during
metastatic progression in the lung distinguish this outlier pair of cells.
As we pursued an understanding of the specific events linked to this
early metastatic phenotype, we presumed that the MNNG and HOS
cells should perform equally well in assays that modeled the early steps
after the arrival in the lung. Indeed, if distinctions between MNNG
and HOS were seen using these assays, we would question the rele-
vance of these modeling approaches. As such, MNNG and HOS were
used as internal controls of assay relevance.
Metastatic Cells Preferentially Resist Apoptotic Death
in the Lung
Continuing on our SCVM analysis of high and low metastatic
cells, we next performed a TUNEL assay of high and low metastatic
cells using two-color fluorescent analysis (green, tumor cell; TUNEL
red, apoptotic cell) in fixed lung sections at discrete points after
SCVM (Figures 2A and W2A). Highly metastatic osteosarcoma cells
had significantly reduced double-positive fluorescent events compared
with the less metastatic cells (Figures 2A and W2B). These differences
in apoptotic rate were seen as early as 3 hours after the arrival of tumor
cells in the lung (P < .001). Confirmatory studies using real time
imaging of a fluorescent-labeled activated caspase 3, again demon-
strated a reduction in apoptotic tumor cells in high compared with
low metastatic osteosarcoma cells (Figures 2B and W2C ). Studies in
high and lowmetastatic murine breast cancer cells yielded similar results
(Figure 2B). It is important to note that apoptotic rates of all high and
low metastatic cells cultured in vitro were not distinguishable (data
not shown). Using the same caspase activation assay and consistent
with our prediction, we found equivalent rates of apoptosis in the lung
(using SCVM) in the high (MNNG) and low (HOS) metastatic cells
Figure 1. SCVM reliably distinguished high versus low metastatic (breast cancer and sarcoma) cells within 6 hours of their arrival in the
lung. SCVM allows in vivo or ex vivo imaging of single fluorescently labeled metastatic cells in the mouse lung [13]. SCVM findings were
seen in a variety of cancer types and biologic settings. (A) Ezrin in murine osteosarcoma (*P = .0043) [13]. (B) E-3 ligase in soft tissue
sarcoma (*P = .0004) [20]. (C) EDG2 in human breast cancer (*P = .0056) [21]. (D) FAS-FAS-ligand in murine osteosarcoma (*P = .0007)
[22]. Scale bars, 400 μm. Of the high and low metastatic cell line pairs examined, only the HOS-MNNG/HOS pair could not be distin-
guished at this early time point (Figure W1). All data represent the mean values ± SD from experiments performed at least three times;
nonparametric two-tailed t test.
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(data not shown). Collectively, these data suggest that early resistance
against apoptotic death is a defining feature of highly metastatic cells.
Akt Is Not, but PKC Is, Associated with the Early Metastatic
Advantage of Highly Metastatic Cells
Using both genetic and pharmacologic approaches in sarcoma and
breast carcinoma cells, we did not find evidence to link the Akt path-
way with the observed survival phenotype of highly metastatic cells
(Figures 3 and W3). We constitutively activated Akt1 in the less-
metastatic AS1.46 cells by retrovirus infection of a myristoylated
Akt construct (Figure W3, A and B). After Akt activation, we found
no difference in the early metastatic phenotype in the lung using
both SCVM and caspase activation assays (Figure W3, C and D).
A pharmacological approach was then asked if an Akt1/2 inhibitor
(PH domain dependent) would influence the early metastatic survival
phenotype (Figure 3). Again, no difference in the metastatic behavior
of highly metastatic (murine and human) osteosarcoma or breast
cancer cells was seen after Akt pathway inhibitor exposure (Figure 3A).
Figure 2. The highly metastatic phenotype is linked to an ability to
resist apoptosis in the lung. (A) Red fluorescent TUNEL staining of
lung, after SCVM, allowed acquisition and enumeration of double-
positive (green/red) tumor cells (green) undergoing apoptosis (red)
using confocal microscopy at 1, 3, and 6 hours after their arrival of
cells in the lung (3 hours; *P < .0001). “% of Apoptotic Tumor
Cells” was determined from the number of double-positive green
and red apoptotic tumors over the total number of green tumor
cells. Actual numbers of imaged green/red and green cells are pro-
vided below each bar. Representative images are presented in
Figure W2. (B) The number of apoptotic (caspase 3 activated) tumor
cells was significantly lower in high metastatic osteosarcoma cells
(*P= .0015) and breast cancer cells (**P= .0223) 1 hour after tumor
cell injection. As expected, no differences in caspase activationwere
observed between the MNNG and HOS osteosarcoma cell pairs,
which were not distinguishable within 6 hours of their arrival in the
lung. All data represent the mean values ± SD from experiments
performed at least three times; Fisher exact test.
Figure 3.Modulation of the Akt survival pathway does not change the
early metastatic phenotype. (A) PuMA was performed using various
GFP-labeled highly metastatic cell lines treated with 1 μMAkt inhibitor
or vehicle for 4 days. The antitumor antibiotic 7-cyanoquinocarcinol
(DX-52-1; + Cont), an agent that markedly affected cell survival
in vitro and reduced metastatic cell numbers in PuMA, was used
as a positive control for maximal inhibition of cell survival compared
to the untreated negative control (– Cont). The inhibition of Akt phos-
phorylation (AktSer473), after 1 μM Akt inhibitor exposure, was con-
firmed byWestern analysis. (B) PuMAwas performed by injection of
GFP-labeled low metastatic AS1.46 cells for 4 days. PuMA cultures
with GFP-labeled lowmetastatic AS1.46 cells were treated with vehi-
cle, PI3 kinase activator (740-Y-P), or DX-52-1. The activation of Akt
pathway, after 740-Y-P exposure for 2 hours, was confirmed byWest-
ern analysis. Specificity of this activation was confirmed by the lack of
ERK1/2 phosphorylation at the same exposures. Pulmonary metasta-
sis survival index was calculated by dividing the tumor burden (total
fluorescence area) in the Akt inhibitor–treated lung section by that of
control-treated lung section. All data represent the mean values ± SD
from experiments performed at least three times; one-way ANOVA.
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Concordantly, no enhancement of early metastatic phenotype was seen
after exposure of the less-metastatic AS1.46 cells to the Akt pathway
activator (Figure 3B).
To begin to define alternative survival pathways responsible for the
early metastatic resistance to apoptosis, we evaluated inhibitors of
mTOR, PKC, Src, and MAPK within the PuMA. The activity of each
inhibitor on the intended signaling pathway was confirmed byWestern
analysis of informative downstream targets at doses shown to have no
effect on the cell line growth in vitro (Figure 4A). Of the agents
screened, PKC inhibition with UCN-01 was found to most negatively
influence the early metastatic phenotype of the breast cancer and sar-
coma cell lines screened (P < .01; Figure 4, B and C). Consistent with
these results, two distinct PKC inhibitors that both target classic PKC
isoforms, UCN-01 and Ro31-8220, significantly inhibited early meta-
static survival of murine and human osteosarcoma and breast cancer
cells in the PuMA (P < .01; Figure 5).
The Process of Pulmonary Metastatic Progression Is
Predominantly Sensitive to PKC Inhibition
Given the previously recognized toxicity of PKC inhibitors, at their
maximally tolerated dose, we first defined the minimum dose of PKC
Figure 4. PKC pathway activation mediates survival of metastatic cancer cells. (A) The relevant target modulation of each pathway (Akt,
mTOR, PKC, Src, and MAPK) inhibitor at the exposures that do not influence cell proliferation was confirmed by Western analysis. (B)
PuMA cultures (K7M2 cells) were treated with pathway inhibitors or DX-52-1 as a positive control (+ Cont) compared to untreated cells
(– Cont). PuMA metastatic burden was significantly lower in PKC inhibitor–treated group. Fluorescent cells (white arrows) have been
confirmed as tumor cells by hematoxylin and eosin staining of lung sections in the PuMA (data not shown). Scale bar, 400 μm.
(C) Pulmonary metastasis survival index was calculated by dividing the tumor burden (area of fluorescence) in the inhibitor-treated lung
section by that of control-treated lung section. PKC- and DX-52-1–treatedmetastatic tumor burden was significantly lower than the control
group (*P < .01). All data represent the mean values ± SD from experiments performed at least three times; one-way ANOVA.
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inhibitor that could target the PKC pathway in vivo (data not shown).
At these effective targeting exposures, we found no effect of PKC inhi-
bition on osteosarcoma cell growth in vitro (Figure 6A). However, in
support of our hypothesis of the unique requirements of metastatic cells
for PKC, we found a complete inhibition of metastatic progression in
the PuMA (Figure 6B) and, more importantly, marked and effective
reduction metastatic burden in vivo (Figure 6, C and D) after exposure
to the PKC inhibitors.
Discussion
An enhanced understanding of the biology of pulmonary metastasis is
needed to improve outcomes for cancer patients. We previously studied
the influence of several genes on the metastatic phenotype of cancer
using a novel assay, SCVM, which allowed the evaluation of single
metastatic cancer cells as they enter the lung [13]. A consistent post hoc
observation from these imaging studies was that nearly all high versus low
metastatic cells could be distinguished within the first 6 hours of the
arrival of cells in the lung [13,20–22,26]. These observations, in both
murine and human breast cancer and sarcoma, suggested that the meta-
static phenotype was notably defined by the ability of metastatic cells to
endure stresses early hours after their arrival in the lung.
On the basis of studies of metastatic inefficiency conducted in
chick embryos, we then asked if the difference in early metastatic
advantage for highly metastatic cells may be related to their ability
to survive in the lung. We found that apoptotic rates, measured by
caspase activation and TUNEL expression, are consistently lower in
high compared to low metastatic cells. Previous reports have sug-
gested the importance of apoptosis resistance as a feature of metastatic
cells. Our data support and extend these findings by emphasizing the
timing, context, and reproducibility of this important feature of me-
tastatic cells (i.e., early after the arrival of cells at the secondary site)
using relevant assays that model tumor interaction with the lung micro-
environment in a number of isogenic cell line pairs. Collectively, these
findings are consistent with a recurring hypothesis that the arrival of
single cells in the lung is a stressful event. The stresses experienced
by single cancer cells are likely related to differences in the micro-
environment at the secondary site compared to the primary site, includ-
ing differences in tissue oxygen tension [27], reactive species [28],
inflammation [29–31], nutritional sources [32], pH, and other meta-
bolic features [33]. We further hypothesize that cells that are able to
resist these stresses, survive, progress, and yield metastasis [34]. It is
important to note that the specific localization of single metastatic
cells within the lung when they are forced to evade apoptosis is un-
known. It is furthermore unclear how interaction of metastatic cells
within the premetastatic and metastatic niches (endothelial cells,
Figure 5. PKC activation is necessary for survival of single meta-
static cells in the lung. (A) Western analysis for downstream target
of PKC, phospho-ERM, was assessed in K7M2 osteosarcoma and
MDA-MB-231 and 4T1 breast cancer cells using 50 nM exposures
of UCN-01 (PKC inhibitor). (B) PuMA using GFP-labeled K7M2,
MDA-MB-231, and 4T1 cells was followed for 4 days. PuMA cultures
were treated with 50 nM PKC inhibitor or DX-52-1 as a positive con-
trol. The number of single metastatic cells (white arrows) in the lung
is significantly decreased (quantification in lower panel) after expo-
sure to PKC inhibitor. Scale bar, 400 μm. (C) Quantification of surviv-
ing single metastatic cells. Pulmonary metastasis survival index was
calculated by dividing the tumor burden (area of fluorescence) in the
PKC inhibitor–treated lung section by that of control-treated lung
section. PKC-treated metastatic burden was significantly lower than
control in K7M2 osteosarcoma and MDA-MB-231 and 4T1 breast
cancer (*P < .01). (D) The use of two distinct PKC inhibitors (UCN-01
and Ro31-8220) significantly inhibited survival of single metastatic
cells in the PuMA in K7M2 osteosarcoma cells (*P < .01). All data
represent the mean values ± SD from experiments performed at
least three times; one-way ANOVA.
Neoplasia Vol. 14, No. 3, 2012 Apoptosis Resistance and Metastasis to the Lung Hong et al. 255
inflammatory cells, and other stromal cells) may prevent or trigger
these apoptotic stresses.
Activation of Akt pathway is recognized as a critical survival signal
of cancer cells [35]. Using both genetic and pharmacologic ap-
proaches in sarcoma and breast carcinoma cells, we could not link
survival of highly metastatic cells, early after their arrival in the lung,
with the Akt pathway. Our findings do not address the likely role
that Akt plays later in progression of metastatic lesions [36–39]. In
the absence of a connection with the Akt survival pathway, we then
used the PuMA to screen other putative survival genes/pathways for
an association with the survival phenotype of highly metastatic cells.
Validated inhibitors of mTOR, PKC, Src, and MAPK were con-
firmed for their specific pathway inhibition in our cell systems. The
only pathway inhibitor found to significantly influence metastatic
progression was a PKC inhibitor. These results were found to be
consistent across species (murine, human), cancer histologic types
(osteosarcoma, breast carcinoma), and two distinct inhibitors of the
classic PKC isoforms. It is important to note that the exposures of
PKC inhibitor used in the PuMA had no influence on cell survival
in conventional tissue culture conditions. PKC pathway activation
has been associated with several steps of metastasis including resistance
to apoptosis, migration, and invasion [40,41]. Recently, pharmacolog-
ical inhibition of PKCα with αV5-3, a novel peptide inhibitor selective
for PKCα, reduced mammary cancer metastasis by increasing their
survival rate in mouse model of breast cancer [42]. The connection
between PKC signaling and metastasis is also supported by studies from
our group, suggesting that classic PKC isoforms regulate the phosphor-
ylation of Ezrin, the prometastatic cytoskeleton linker protein. Because
the PKC inhibitor UNC-01 is undergoing clinical development in
patients with cancer, our data may be useful to conceive of optimized
(tolerable and chronic) treatment schedules that may be active in lim-
iting the survival of single metastatic cells in the lung. Such biologically
based strategies may be quite distinct from the maximally tolerated
dose-intensive schedules that are conventionally advanced into the
clinical arena. It is understood that the metastatic seeding of secondary
sites may occur before and after patients present with either localized or
nonlocalized disease [43]. Our data describe the interaction of single
cells within hours of their arrival in the lung; however, it is reasonable
Figure 6. Pulmonary metastasis was uniquely inhibited after PKC inhibition. (A) The in vitro proliferation of tumor cells was not affected
by PKC inhibitor (UCN-01) at 10 and 50 nM. A modest delay in orthotopic primary tumor growth to human end points was seen after PKC
inhibitor treatment of mice (data not shown). (B) PKC inhibitor (UNC-01) used at exposures of 50 nM significantly inhibited pulmonary
metastatic tumor burden within the PuMA. (C) In vivo experimental pulmonary metastasis was significantly inhibited after a 4-day treat-
ment of mice with UCN-01 compared to vehicle control group. Scale bar, 5 mm. (D) Pulmonary metastatic tumor area was quantified by
measuring the tumor area in the whole lung. PKC-treated metastatic tumor burden was significantly lower than vehicle-treated group in
K7M2 osteosarcoma cells (*P < .05).
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that metastatic cells are exposed to stresses and similar dependencies for
PKC and other signals throughout metastatic progression. This may
include times where single cells extend away from metastatic lesions
during further metastatic progression into the surrounding lung micro-
environment (when metastases metastasize) [44]. As such, there is not
a basis to a priori determine that the targeting of “single” metastatic cells
is “too late” to be helpful to patients. Furthermore, there is currently
insufficient information to know when metastatic cells leave a primary
tumor [45], whether they first seed a sanctuary site (i.e., the bonemarrow)
[46,47] or if subsequent seeding from a site of dormancy to a secondary
organ (i.e., the lung) may occur after a patient presents with localized
disease [48].
In summary, our results suggest the highly metastatic cells and not
low metastatic cells survive and resist apoptosis as single cells early
after their arrival in the lung. This survival advantage for highly meta-
static cells is Akt independent but PKC and caspase 3 dependent.
These data, emerging from studies of breast carcinoma and sarcoma
cells, contribute to a detailed understanding of the steps that are most
commonly defining of the metastatic phenotype and the pathways
responsible for these steps. The translational value of these data sug-
gests an opportunity to target the metastatic phenotype at critical and
uniquely vulnerable states.
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Figure W1. Osteosarcoma (OS) metastatic progress is inefficient as demonstrated by SCVM. (A) Imaging of fluorescently labeled murine
OS cells (highly aggressive K7M2/empty vector [EV] and nonmetastatic K7M2-1.52 [AS1.52]) reveals a loss of most tumor cells by 6 hours
of tumor cell arrival in the lung. Nonetheless, quantification of fluorescent images revealed that less metastatic AS1.52 had a significantly
lower number of tumor cells detected in the lung at 6 hours compared to the highly metastatic K7M2/EV. This difference has been seen in
five of six studies of high versus low metastatic cells, suggesting the early events after the arrival of metastatic cells in the lung are a
defining feature of metastasis (*P = .0109). (B) Uncharacteristically (the single outlier in this observation), the highly aggressive MNNG
and nonmetastatic HOS human osteosarcoma cells showed similar patterns of metastatic inefficiency and cannot be distinguished at
6 hours after tumor cells arrival in the lung. Scale bar, 400 μm (A, B). All data are represented as mean ± SD. As previously reported [13],
SCVM involves the delivery of fluorescent tumor cells to mice. Imaging of tumor cells in the lungs ex vivo is then accomplished using a
fluorescent inverted videomicroscope at specific time points after cell injection. The number of cell imaged 1 hour after injection is used
for normalization of subsequent time points. All data represent the mean values ± SD from experiments performed at least three times;
nonparametric two-tailed t test.
Figure W2. The highly metastatic phenotype of cancer cells is
linked to their ability to resist apoptosis early after their arrival into
the lung. Using 15-μm paraffin sections of the whole lung, we ac-
quired and enumerated both single-positive green tumor cells and
double-positive green/red apoptotic tumor cells using confocal im-
aging, after SCVM. (A) Representative fluorescent images: green
fluorescent, tumor cells; red, TUNEL-positive cells; and double-
positive green/red, cells tumor cells undergoing apoptosis. Blue
represents DAPI counterstaining. (B) Quantification of TUNEL as-
say. “% of Apoptotic Tumor Cells” was determined from the num-
ber of double-positive green and red apoptotic tumors over the
total number of green tumor cells. As early as 3 hours, the percent
of apoptotic tumor cells was lower in highly metastatic compared
to low metastatic cells. All data are represented as mean ± SD
from experiments performed at least three times; Fisher exact test
(3 hours; *P < .0001). The small number of low metastatic cells
(AS1.52) at 6 hours (n = 2 cells) precluded statistical analysis at
that time point; results of each confocal imaging experiment were
repeated in triplicate. (C) Images of real-time in vivo caspase 3 de-
tection: the green fluorescent events are tumor cells, red fluores-
cent events are cells with caspase activation (result of cleavage of
a fluorescent caspase substrate), and double-positive green/red
cells are tumor cells with caspase 3 activation 1 hour after tumor
cell arrival in the lung. Scale bars, 200 μm (A, C).
Figure W3. Genetic activation of the Akt survival pathway does not rescue the low metastatic phenotype of cells early after their arrival in
the lung. (A, B) Expression and characterization of activated Akt in AS1.46 and AS1.52 cell clones. Activated Akt pMSCV was transduced
into nonmetastatic AS1.46 and AS1.52 cell clones. Resultant Akt-activated clones were identified as Akt 25 clone and Akt 45 clone. (C) No
difference in cell number was seen after SCVM quantification of fluorescently labeled AS1.46 empty vector (AS1.46/EV) compared to Akt-
activated clones (actAkt-25AS1.46 and actAkt-45AS1.46) 6 hours after arrival of tumor cells in the lung. (D) Quantification of fluorescently
labeled AS1.52 empty vector (AS1.52/EV), activated Akt 25 AS1.52 (actAkt 25 AS1.52), and activated Akt 45 AS1.52 (actAkt 45 AS1.52)
cells showed no difference cell number in the lung. (E) No difference in the number of caspase-positive tumor cells were seen between
AS1.46 empty vector (AS1.46/EV) and Akt-activated AS1.46 (actAkt-25AS1.46) cells 6 hours after arrival of tumor cells in the lung. Similar
results were seen in a second distinct clone in the both assays (data not shown). All data are represented as mean ± SD (C-E).
